# Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML

> **NCT05177731** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Chen Suning** · enrollment: 188 (actual)

## Conditions studied

- AML, Adult
- Chemotherapy Effect

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** Decitabine for Injection
- **DRUG:** Cytarabine
- **DRUG:** Idarubicin
- **DRUG:** Gilteritinib

## Key facts

- **NCT ID:** NCT05177731
- **Lead sponsor:** Chen Suning
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-03-01
- **Primary completion:** 2024-02-28
- **Final completion:** 2024-12-31
- **Target enrollment:** 188 (ACTUAL)
- **Last updated:** 2024-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05177731

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05177731, "Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05177731. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*